US6323071042
© BusinessWire
12.12.2025
NTRA
LISTED
NASDAQ
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-)...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
NTRA
LISTED
NASDAQ
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study.
Presented today at the San Ant...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
NTRA
LISTED
NASDAQ
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting.
Real-world Signatera Analysis: Oral Presentation on December 6
A real-world analysis of personalized circulating tumor DNA (ctDN...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
05.12.2025
NTRA
LISTED
NASDAQ
Natera Acquires Foresight Diagnostics
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight.
Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company’...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.12.2025
NTRA
LISTED
NASDAQ
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
NTRA
LISTED
NASDAQ
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12.
The presentations encompass aggregated data from more than 50,000 patients in real-world evi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
NTRA
LISTED
NASDAQ
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours during the company’s fourth annual Volunteer Month. This initiative takes place each October and is organized by Natera Nurtures, the company’s employee resource group dedicated to com...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
NTRA
LISTED
NASDAQ
Natera Integrates with Flatiron Health’s OncoEMR® Platform
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera’s oncology testing portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Reco...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
NTRA
LISTED
NASDAQ
Natera Reports Third Quarter 2025 Financial Results
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025.
Recent Financial Highlights
Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
NTRA
LISTED
NASDAQ
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded p...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
NTRA
LISTED
NASDAQ
Natera to Report its Third Quarter Results on November 6, 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.
Earnings Conference Call Information...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
NTRA
LISTED
NASDAQ
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is evaluating a blood-based screening test for the detection of CRC and advanced adenomas (AA). This latest analysis from the U.S. based, prospective PROCEED-CRC clinical trial (NCT06620627) fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
27.10.2025
NTRA
LISTED
NASDAQ
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Natera Inc. (NASDAQ: NTRA) breached their fiduciary duties to shareholders.
If you currently own Natera stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a c...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
NTRA
LISTED
NASDAQ
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The findings demonstrate that Signatera can expand the adjuvant treatment window and guide the use of adjuvant atezolizumab (Tec...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
NTRA
LISTED
NASDAQ
Natera Named to Fast Company’s Next Big Things in Tech List
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company’s 2025 Next Big Things in Tech list. Honored for its Signatera personalized molecular residual disease (MRD) test, Natera was one of five companies recognized in the health and medicine category.
This annua...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
NTRA
LISTED
NASDAQ
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includ...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
NTRA
LISTED
NASDAQ
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six oral presentations, reinforcing Natera’s position as a l...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
NTRA
LISTED
NASDAQ
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for pat...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
NTRA
LISTED
NASDAQ
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer.
Uterine cancer is the m...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
NTRA
LISTED
NASDAQ
Natera Provides Update on Patent Litigation with NeoGenomics
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.
The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics’...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
NTRA
LISTED
NASDAQ
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current stan...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
NTRA
LISTED
NASDAQ
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2025
NTRA
LISTED
NASDAQ
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research.
These publications span high-impact journals – such as Natur...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2025
NTRA
LISTED
NASDAQ
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision s...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
NTRA
LISTED
NASDAQ
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group.
IMvigor011 utilizes the Signatera ctDNA test in patient...
Themefolio
Profiler
Peergroup
© BusinessWire
01.08.2025
NTRA
LISTED
NASDAQ
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA.
The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive coll...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
NTRA
LISTED
NASDAQ
Natera to Report Its Second Quarter Results on August 7, 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Info...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
NTRA
LISTED
NASDAQ
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior t...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
NTRA
LISTED
NASDAQ
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ab...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
NTRA
LISTED
NASDAQ
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI).
The clinical performance of the assay was analyzed in a cohort of ~20...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
NTRA
LISTED
NASDAQ
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
NTRA
LISTED
NASDAQ
Natera Announces Medicare Coverage for Signatera™ Genome
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779.
This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer im...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
NTRA
LISTED
NASDAQ
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study analyzed the performance of Signatera Genome in a cohort...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
NTRA
LISTED
NASDAQ
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL.
Together with its collaborators, Natera will showcase...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
NTRA
LISTED
NASDAQ
Natera Reports First Quarter 2025 Financial Results
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.
Recent Strategic and Financial Highlights
Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an incr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
NTRA
LISTED
NASDAQ
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025.
Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
NTRA
LISTED
NASDAQ
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection.
Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
NTRA
LISTED
NASDAQ
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera’s personalized molecular residual disease (MRD) test, in patients with soft tissue and bone sarcomas. Results of the study (Utilizing Circ...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
NTRA
LISTED
NASDAQ
Natera to Report its First Quarter Results on May 8, 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
NTRA
LISTED
NASDAQ
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA.
DEFINE-HT is the firs...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
NTRA
LISTED
NASDAQ
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States.
This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 202...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
NTRA
LISTED
NASDAQ
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL.
Highlights from AACR include:
An oral presentation titled “Large-scale Genomic Pr...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
NTRA
LISTED
NASDAQ
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.
DEFINE-HT is the first prospective, multicenter study i...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
NTRA
LISTED
NASDAQ
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
NTRA
LISTED
NASDAQ
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera’s extensive intellectual property estate, including a strong portfolio o...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
NTRA
LISTED
NASDAQ
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024.
Recent Financial Highlights
Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
NTRA
LISTED
NASDAQ
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
NTRA
LISTED
NASDAQ
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call In...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
NTRA
LISTED
NASDAQ
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC).
In its upda...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
NTRA
LISTED
NASDAQ
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States.
Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is av...
Themefolio
Profiler
Peergroup
© BusinessWire
25.01.2025
NTRA
LISTED
NASDAQ
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
NTRA
LISTED
NASDAQ
Natera to Present New Data at the 2025 ASCO GI Symposium
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23 – 25, 2025 in San Francisco, CA.
BESPOKE CR...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
NTRA
LISTED
NASDAQ
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top healthcare technology CEOs for 2024, as determined by Healthcare Technology Report. Chapman was also named “BioTechnology Innovator of the Year” in 2024, in the fourth annual BioTech Br...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
NTRA
LISTED
NASDAQ
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on i...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
NTRA
LISTED
NASDAQ
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following:
Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
NTRA
LISTED
NASDAQ
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, Jan. 15, 2025 at 9:00 a.m. PT (12:00 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
NTRA
LISTED
NASDAQ
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests.
On December 10, 2024, the District Court for the Middle District of North Carolina (“The District Court”) granted Natera’s request to inc...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
NTRA
LISTED
NASDAQ
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinica...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
NTRA
LISTED
NASDAQ
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer ris...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
NTRA
LISTED
NASDAQ
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company’s clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT).
Natera’s study is the largest clinical validatio...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
